Non-steroidal anti-inflammatory. Potently inhibits human transthyretin amyloid fibril formation. Alters ion fluxes through the plasma membrane. Potent non-specific blocker of cation and anion channels, commonly used to block currents through TRP channels and receptor-operated channels.
Store at Room Temperature. The product can be stored for up to 12 months.
Soluble in DMSO to 100 mM and in ethanol to 100 mM
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Use at an assay dependent concentration.
Functional Studies - Flufenamic acid (ab120354)
ab51110 staining AMPKα 1 + AMPKα 2 (phosphoT172) in HeLa cells treated with flufenamic acid (ab120354), by ICC/IF. Increase in AMPKα 1 + AMPKα 2 (phosphoT172) nuclear expression correlates with increased concentration of flufenamic acid, as described in literature. The cells were incubated at 37°C for 30 minutes in media containing different concentrations of ab120354 (flufenamic acid) in DMSO, fixed with 4% formaldehyde for 10 minutes at room temperature and blocked with PBS containing 10% goat serum, 0.3 M glycine, 1% BSA and 0.1% tween for 2h at room temperature. Staining of the treated cells with ab51110 (5 µg/ml) was performed overnight at 4°C in PBS containing 1% BSA and 0.1% tween. A DyLight 488 goat anti-rabbit polyclonal antibody (ab96899) at 1/250 dilution was used as the secondary antibody.
This product has been referenced in:
Hotta A et al. The effects of flufenamic acid on spontaneous activity of smooth muscle tissue isolated from the guinea-pig stomach antrum. J Smooth Muscle Res41:207-20 (2005).
Read more (PubMed: 16258234) »
Peterson SA et al. Inhibiting transthyretin conformational changes that lead to amyloid fibril formation. Proc Natl Acad Sci U S A95:12956-60 (1998).
Read more (PubMed: 9789022) »